Ex­clu­sive: With $8M, neu­ro start­up Mod­u­lo Bio emerges to test small mol­e­cules for ALS, de­men­tia in CEO’s per­son­al mis­sion

Em­bark­ing on a per­son­al mis­sion af­ter his best friend’s moth­er was di­ag­nosed with a mu­ta­tion-dri­ven case of fron­totem­po­ral de­men­tia, Michael Horowitz has pulled to­geth­er $8 mil­lion in ven­ture fund­ing at Mod­u­lo Bio to cre­ate small mol­e­cules for neu­rode­gen­er­a­tive dis­eases.

The San Diego and Bay Area biotech will se­lect its lead de­vel­op­ment can­di­date and some back­up op­tions with­in six months and then raise a Se­ries A to in­ves­ti­gate ther­a­peu­tics for C9orf72 mu­ta­tion-dri­ven cas­es of ALS and fron­totem­po­ral de­men­tia, Horowitz told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER